A

Adverum Biotechnologies
D

ADVM

2.71000
USD
0.03
(1.12%)
مغلق
حجم التداول
1,547
الربح لكل سهم
-6
العائد الربحي
-
P/E
-0
حجم السوق
56,613,886
أصول ذات صلة
A
ALLO
-0.01000
(-0.66%)
1.49500 USD
BMRN
BMRN
-0.765
(-1.28%)
59.010 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
N
NTLA
0.830
(6.50%)
13.595 USD
REGN
REGN
-1.20
(-0.21%)
563.22 USD
S
SGMO
-0.01190
(-1.99%)
0.58600 USD
S
SRPT
-0.970
(-7.53%)
11.910 USD
V
VYGR
-0.08000
(-2.41%)
3.23500 USD
المزيد
الأخبار المقالات

العنوان: Adverum Biotechnologies

القطاع: Healthcare
الصناعة: Biotechnology
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.